Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management

Clinical Genetics

Volumn 86, Issue 1, 2014, Pages 12-20

  Ortega, V E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Admixture mapping; Asthma; Beta agonist; Gene; Genome wide association study; Pharmacogenetics; Response heterogeneity; Single nucleotide polymorphism

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; NITRIC OXIDE; ADRB2 PROTEIN, HUMAN;

ADVERSE DRUG REACTION; ASTHMA; BIOSYNTHESIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DISEASE MANAGEMENT; GENE FREQUENCY; GENETICS; HUMAN; PERSONALIZED MEDICINE; PROCEDURES; SIGNAL TRANSDUCTION; TRENDS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; DISEASE MANAGEMENT; GENE FREQUENCY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 84901691957     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12377     Document Type: Review

References (57)

1. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000: 56: 1054-1070.
2. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998: 8: 283-289.
3. Pearce N, Grainger J, Atkinson M et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990: 45: 170-175.
4. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972: 105: 883-890.
5. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993: 306: 1034-1037.
6. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006: 129: 15-26.
7. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006: 144: 904-912.
8. FDA Drug Safety Communication. FDA Requires Post-Market Safety Trials For Long-Acting Beta-Agonists (LABAs) 2011, from http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Accessed on July 10, 2012.
9. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011: 364: 2473-2475.
10. Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 2008: 29: 499-516.
11. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009: 33: 21-32.
12. Anderson HR, Ayres JG, Sturdy PM et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005: 330: 117.
13. Wechsler ME, Castro M, Lehman E et al. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med 2011: 184: 1247-1253.
14. Lemanske RF Jr, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010: 362: 975-985.
15. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010: 363: 1715-1726.
16. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013: 368: 2455-2466.
17. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993: 8: 334-339.
18. Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000: 97: 10483-10488.
19. Hawkins GA, Tantisira K, Meyers DA et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006: 174: 1101-1109.
20. Chung LP, Waterer G, Thompson PJ. Pharmacogenetics of beta2 adrenergic receptor gene polymorphisms, long-acting beta-agonists and asthma. Clin Exp Allergy 2011: 41: 312-326.
21. Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. Immunol Allergy Clin North Am 2007: 27: 665-684 vii.
22. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995: 13: 25-33.
23. Bleecker ER, Yancey SW, Baitinger LA et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006: 118: 809-816.
24. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004: 364: 1505-1512.
25. Wechsler ME, Kunselman SJ, Chinchilli VM et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009: 374: 1754-1764.
26. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007: 370: 2118-2125.
27. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000: 55: 762-767.
28. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997: 100: 3184-3188.
29. Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005: 171: 563-570.
30. Israel E, Drazen JM, Liggett SB et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000: 162: 75-80.
31. Wechsler ME, Lehman E, Lazarus SC et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006: 173: 519-526.
32. Bleecker ER, Nelson HS, Kraft M et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010: 181: 676-687.
33. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004: 57: 68-75.
34. Bonini M, Permaul P, Kulkarni T et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Resp Crit Care Med 2013: 188: 1407-1412.
35. Lipworth BJ, Basu K, Donald HP et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin Sci (Lond) 2013: 124: 521-528.
36. Genomes Project Consortium, Abecasis GR, Auton A et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012: 491: 56-65.
37. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 2014: 133: 16-26.
38. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993: 268: 23116-23121.
39. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001: 421: 141-147.
40. Thomsen M, Nordestgaard BG, Sethi AA, Tybjaerg-Hansen A, Dahl M. Beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012: 39: 558-566.
41. Ortega VE, Hawkins GA, Moore WC et al. Effect of rare genetic variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population. Lancet Respir Med 2014: 2: 204-213.
42. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005: 14: 1671-1677.
43. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 2011: 36: 399-405.
44. Small KM, Brown KM, Theiss CT, Seman CA, Weiss ST, Liggett SB. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 2003: 13: 535-541.
45. Poon AH, Tantisira KG, Litonjua AA et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acut-e bronchodilator response in asthma. Pharmacogenet Genomics 2008: 18: 373-382.
46. Drake KA, Torgerson DG, Gignoux CR et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol 2014: 132: 370-378.
47. Litonjua AA, Lasky-Su J, Schneiter K et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008: 178: 688-694.
48. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 2010: 20: 179-186.
49. Duan QL, Gaume BR, Hawkins GA et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 2011: 183: 449-454.
50. Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichael A, Manolopoulos VG. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting beta2-agonists in asthmatic children. Pharmacogenomics 2012: 13: 1363-1372.
51. Himes BE, Jiang X, Hu R et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet 2012: 8: e1002824.
52. Duan QL, Lasky-Su J, Himes BE et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014: 14: 41-47.
53. Zhu X, Tang H, Risch N. Admixture mapping and the role of population structure for localizing disease genes. Adv Genet 2008: 60: 547-569.
54. Choudhry S, Que LG, Yang Z et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics 2010: 20: 351-358.
55. Himes BE, Wu AC, Duan QL et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 2009: 10: 1393-1412.
56. Duan QL, Du R, Lasky-Su J et al. A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J 2013: 13: 130-136.
57. Ortega VE, Wechsler ME. Asthma pharmacogenetics: responding to the call for a personalized approach. Curr Opin Allergy Clin Immunol 2013: 13: 399-409.